NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) to Lantheus Holdings, Inc. (“Lantheus”) for 0.2502 shares of Lantheus stock for each share of Progenics stock is fair to Progenics shareholders. On behalf of Progenics shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
If you are a Progenics shareholder and would like to discuss your legal rights and options, please visit Progenics Merger or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.
The Progenics merger investigation concerns whether Progenics and its Board of Directors violated the federal securities laws and/or their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for Progenics shareholders; (2) determine whether Lantheus is underpaying for Progenics; and (3) disclose all material information necessary for Progenics shareholders to adequately assess and value the merger consideration.
If you are a Progenics shareholder and would like to discuss your legal rights and options, please visit https://halpersadeh.com/actions/progenics-pharmaceuticals-inc-pgnx-stock-merger-lantheus/ or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com